2seventy bio (TSVT) Competitors $4.95 -0.01 (-0.20%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$4.96 +0.00 (+0.10%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSVT vs. MLYS, NRIX, VIR, NTLA, COLL, RCUS, RCKT, XNCR, ZYME, and XERSShould you be buying 2seventy bio stock or one of its competitors? The main competitors of 2seventy bio include Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), Zymeworks (ZYME), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. 2seventy bio vs. Mineralys Therapeutics Nurix Therapeutics Vir Biotechnology Intellia Therapeutics Collegium Pharmaceutical Arcus Biosciences Rocket Pharmaceuticals Xencor Zymeworks Xeris Biopharma 2seventy bio (NASDAQ:TSVT) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability. Does the MarketBeat Community believe in TSVT or MLYS? 2seventy bio received 7 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 47.17% of users gave 2seventy bio an outperform vote. CompanyUnderperformOutperform2seventy bioOutperform Votes2547.17% Underperform Votes2852.83% Mineralys TherapeuticsOutperform Votes18100.00% Underperform VotesNo Votes Do insiders and institutionals believe in TSVT or MLYS? 93.9% of 2seventy bio shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 7.2% of 2seventy bio shares are held by company insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to TSVT or MLYS? In the previous week, 2seventy bio had 2 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 13 mentions for 2seventy bio and 11 mentions for Mineralys Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.74 beat 2seventy bio's score of 0.50 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 2seventy bio 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, TSVT or MLYS? Mineralys Therapeutics has lower revenue, but higher earnings than 2seventy bio. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than 2seventy bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio2seventy bio$45.62M5.60-$217.57M-$1.86-2.66Mineralys TherapeuticsN/AN/A-$177.81M-$3.64-4.61 Do analysts prefer TSVT or MLYS? 2seventy bio presently has a consensus target price of $6.67, indicating a potential upside of 34.68%. Mineralys Therapeutics has a consensus target price of $27.00, indicating a potential upside of 60.91%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than 2seventy bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 2seventy bio 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.38Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TSVT or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. 2seventy bio's return on equity of -53.65% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 2seventy bio-207.25% -53.65% -23.67% Mineralys Therapeutics N/A -67.97%-62.40% Which has more risk and volatility, TSVT or MLYS? 2seventy bio has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Summary2seventy bio beats Mineralys Therapeutics on 10 of the 18 factors compared between the two stocks. Remove Ads Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSVT vs. The Competition Export to ExcelMetric2seventy bioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.36M$6.99B$5.68B$8.30BDividend YieldN/A2.73%4.55%4.02%P/E Ratio-2.667.2324.5819.25Price / Sales5.60232.30388.0794.32Price / CashN/A65.6738.1634.64Price / Book0.986.617.084.46Net Income-$217.57M$142.13M$3.19B$247.07M7 Day Performance-0.20%-1.51%-0.94%0.14%1 Month Performance91.12%-3.46%3.55%-4.39%1 Year Performance-0.20%-5.32%14.29%4.85% 2seventy bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSVT2seventy bio2.9408 of 5 stars$4.95-0.2%$6.67+34.7%+1.0%$255.36M$45.62M-2.66440MLYSMineralys Therapeutics2.8462 of 5 stars$16.17-4.1%$27.00+67.0%+29.9%$1.02BN/A-4.4428Gap UpHigh Trading VolumeNRIXNurix Therapeutics2.0249 of 5 stars$13.34+2.7%$30.88+131.5%-7.0%$1.01B$54.55M-4.62300VIRVir Biotechnology3.7586 of 5 stars$7.20+3.9%$35.67+395.4%-30.5%$987.43M$63.71M-1.84580Positive NewsNTLAIntellia Therapeutics4.4718 of 5 stars$9.31+3.4%$37.56+303.4%-67.5%$963.74M$57.88M-1.71600Analyst RevisionCOLLCollegium Pharmaceutical4.0272 of 5 stars$30.56+1.7%$43.60+42.7%-24.9%$962.21M$631.45M13.17210Analyst ForecastAnalyst RevisionRCUSArcus Biosciences2.3158 of 5 stars$9.15+2.3%$30.25+230.8%-49.1%$961.49M$258M-2.90500RCKTRocket Pharmaceuticals4.7764 of 5 stars$8.73+3.6%$43.00+392.6%-69.6%$930.88MN/A-3.17240Positive NewsXNCRXencor3.3791 of 5 stars$12.95-1.9%$34.38+165.4%-46.0%$912.48M$110.49M-4.05280ZYMEZymeworks2.7202 of 5 stars$13.05+2.6%$21.00+60.9%+23.1%$907.98M$76.30M-8.70460Insider TradePositive NewsXERSXeris Biopharma3.3041 of 5 stars$5.87+1.0%$5.92+0.8%+178.2%$903.63M$203.07M-13.04290High Trading Volume Remove Ads Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Nurix Therapeutics Competitors Vir Biotechnology Competitors Intellia Therapeutics Competitors Collegium Pharmaceutical Competitors Arcus Biosciences Competitors Rocket Pharmaceuticals Competitors Xencor Competitors Zymeworks Competitors Xeris Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSVT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
